Beigene Ltd
ONC
View Detailed Chart
324.340USD
-11.330-3.38%
Close 09/12, 16:00（ET）Quotes delayed by 15 min
32.76BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.38%
5 Days
-5.11%
1 Month
+5.47%
6 Months
+27.41%
Year to Date
+75.59%
1 Year
+63.40%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
22
analysts
Buy
Current Rating
363.033
Target Price
+11.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 169.10% year-on-year.
Undervalued
The company’s latest PE is -193.08, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 63.29M shares, increasing 0.72% quarter-over-quarter.
Held by PRIMECAP Management
Star Investor PRIMECAP Management holds 5.09M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Ticker SymbolONC
CompanyBeigene Ltd
CEOMr. John Victor Oyler
Website
Related Instruments
-0.94%
+1.35%
-1.84%
+0.10%
-7.26%
-2.70%
+1.83%
-1.40%
-0.06%
-1.06%
+0.20%
+0.50%
-3.68%
-1.37%
-1.67%
-1.65%
+0.67%
0.00%
-3.66%
-4.27%
